Cargando…
Subcutaneous Immunoglobulin Therapy in the Chronic Management of Myasthenia Gravis: A Retrospective Cohort Study
BACKGROUND: Immunoglobulin therapy has become a major treatment option in several autoimmune neuromuscular disorders. For patients with Myasthenia Gravis (MG), intravenous immunoglobulin (IVIg) has been used for both crisis and chronic management. Subcutaneous Immunoglobulins (SCIg), which offer the...
Autores principales: | Bourque, P. R., Pringle, C. E., Cameron, W., Cowan, J., Chardon, J. Warman |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973986/ https://www.ncbi.nlm.nih.gov/pubmed/27490101 http://dx.doi.org/10.1371/journal.pone.0159993 |
Ejemplares similares
-
Usefulness of subcutaneous immunoglobulin therapy in the management of myasthenia gravis: a retrospective cohort study
por: Barnay, Marlène, et al.
Publicado: (2022) -
Long-term treatment of refractory myasthenia gravis with subcutaneous immunoglobulin
por: Kovács, Edina, et al.
Publicado: (2017) -
Subcutaneous Immunoglobulins are a Valuable Treatment Option in Myasthenia Gravis
por: Garnero, Martina, et al.
Publicado: (2018) -
Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial
por: Putko, Brendan N., et al.
Publicado: (2020) -
Extracorporeal Immunoglobulin Elimination for the Treatment of Severe Myasthenia Gravis
por: Blaha, M., et al.
Publicado: (2010)